– FRANCE, Paris – Cellectis (Alternext: ALCLS / NASDAQ:CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited CAR T-cells, today announced that it has appointed Rainer Boehm, M.D. and Hervé Hoppenot to its Board of Directors.
“We are delighted to welcome Rainer Boehm and Hervé Hoppenot to our Board. Rainer’s experience in drug commercialization will be invaluable as we work to develop the next generation CAR T-cell immunotherapies. Hervé brings deep expertise in oncology which will be a major benefit to our team we continue to innovate to bring UCART product candidates to the clinic,” said André Choulika, CEO Cellectis. “With these two esteemed leaders, we are adding to the expertise of our Board of Directors to help guide Cellectis into our next phase.”
Rainer Boehm spent 29 years at Novartis, working locally, regionally and globally in various Senior Management roles, after building his career in Marketing & Sales and Medical Affairs. He led all emerging markets regions as well as the United States and Canada, either for Oncology or the Pharmaceuticals division. His most recent assignments were Chief Commercial and Medical Affairs Officer globally for Novartis Pharma, as well as ad interim CEO and Division Head Pharma. Rainer launched and oversaw the commercialization of many brands during his career, amongst them Femara, Zometa and Glivec, as well as Cosentyx and Entresto. His broad interests include leadership development, coaching and mentoring, access to medicines and new business models including solutions to leverage digital medicines and real world evidence. Rainer has a medical degree from the University of Ulm in Germany, and a Master of Business Administration from Schiller University in France.
“I am honored to join the Board and look forward to providing strategic advice on drug commercialization to strengthen Cellectis’ market leading position. Cellectis is a company with tremendous potential,” said Rainer Boehm, Cellectis’ newest Board member. “I see exciting opportunities for Cellectis to address unmet medical needs and make a meaningful difference in people’s lives. What Cellectis is accomplishing is transformative and we have the potential to move the needle forward for healthcare in a positive way. ”
Hervé Hoppenot joined Incyte Corporation in 2014 as President and Chief Executive Officer, and was appointed Chairman of the Board of Directors in 2015. Incyte is one of the fastest growing biopharmaceutical companies in the U.S. Incyte’s team of more than 1,000 scientists, clinicians, and other team members operating in 15 countries, strives to discover and develop first-in-class and best-in-class medicines for cancer and other diseases. The Company is advancing a diverse portfolio of large and small molecules comprised of 18 development candidates against 14 different molecular targets and in 2016 Incyte reported revenue of more than $1 billion.
Prior to joining Incyte, Mr. Hoppenot was the President of Novartis Oncology, which included $11 billion in global sales, the largest oncology pipeline in the industry and 8000 employees in 50 countries. Prior to joining Novartis in 2003, Mr. Hoppenot started his career in 1983 with Rhone Poulenc, later known as Aventis, where he served in several senior roles of increasing responsibility, including Vice President of Oncology and Head of the US Oncology business unit. He and his family are dual citizens of France and the United States, having moved to the U.S. in 1991.
“Despite many advances in oncology, there remains a need to continue to advance the science to meet the needs of patients. Through its work in developing CAR T immunotherapies, Cellectis has an opportunity to make a significant contribution to the treatment of cancer,” Mr. Hoppenot said. “I am excited to be joining the Cellectis Board during this important time of growth.”
For more information : http://www.cellectis.com
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.